We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.76B
AUM Growth
+$192M
Cap. Flow
+$451M
Cap. Flow %
16.36%
Top 10 Hldgs %
46.52%
Holding
86
New
11
Increased
24
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$117M
2
CGEM icon
Cullinan Oncology
CGEM
+$92.4M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$74.2M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$51.3M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$50.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$45.6M
2
RVMD icon
Revolution Medicines
RVMD
+$19M
3
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$16.5M
4
ANAB icon
AnaptysBio
ANAB
+$9.07M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$7.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.65%
2 Financials 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACIU icon
26
AC Immune
ACIU
$225M
$35M 1.27%
7,062,379
+127,200
+2% +$739K
KDNY
27
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$29.4M 1.07%
+1,800,000
New +$25.6M
KURA icon
28
Kura Oncology
KURA
$790M
$28.9M 1.05%
2,064,212
+429,100
+26% +$6.95M
TYRA icon
29
Tyra Biosciences
TYRA
$1.86B
$26.4M 0.96%
1,873,332
+178,399
+11% +$3.54M
SPRO icon
30
Spero Therapeutics
SPRO
$68.3M
$25.4M 0.92%
1,585,615
-223,737
-12% -$3.55M
CTMX icon
31
CytomX Therapeutics
CTMX
$686M
$25.1M 0.91%
+5,803,700
New +$34M
REPL icon
32
Replimune Group
REPL
$885M
$25.1M 0.91%
926,529
– –
ACRS icon
33
Aclaris Therapeutics
ACRS
$725M
$24.7M 0.9%
1,695,904
+322,860
+24% +$4.89M
IMA
34
ImageneBio Inc
IMA
$62.9M
$22.6M 0.82%
149,864
-2,809
-2% -$456K
CTIC
35
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$22.1M 0.8%
8,929,690
– –
ALPN
36
DELISTED
Alpine Immune Sciences Inc
ALPN
$22M 0.8%
1,589,495
– –
WHWK
37
Whitehawk Therapeutics
WHWK
$190M
$21.7M 0.79%
899,392
-247,660
-22% -$6.22M
OVID icon
38
Ovid Therapeutics
OVID
$420M
$21.3M 0.77%
6,631,051
– –
PVLA
39
Palvella Therapeutics
PVLA
$2.02B
$20.1M 0.73%
66,603
– –
JANX icon
40
Janux Therapeutics
JANX
$923M
$20.1M 0.73%
1,017,314
– –
PYXS icon
41
Pyxis Oncology
PYXS
$167M
$19.7M 0.71%
+1,791,351
New +$20.5M
CALT
42
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$18.6M 0.67%
750,000
– –
NGM
43
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$16.9M 0.61%
955,000
– –
PNT
44
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$16.4M 0.59%
2,920,526
+148,300
+5% +$1.11M
SLN
45
Silence Therapeutics
SLN
$528M
$15.6M 0.57%
666,666
– –
INFI
46
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$14.3M 0.52%
6,353,645
-2,030,000
-24% -$5.1M
STRO icon
47
Sutro Biopharma
STRO
$405M
$13.8M 0.5%
92,515
+9,832
+12% +$1.76M
CBIO
48
Crescent Biopharma
CBIO
$522M
$13.7M 0.5%
95,443
– –
DAWN
49
DELISTED
Day One Biopharmaceuticals
DAWN
$13.6M 0.49%
809,282
-1,002
-0.1% -$20.6K
COGT icon
50
Cogent Biosciences
COGT
$6.7B
$13.1M 0.48%
1,532,282
– –
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2021 Portfolio in Review

As of Q4 2021, BVF Inc held 86 positions worth $2.76B, up 7.5% from $2.56B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

BVF Inc deployed $451M of net new capital in Q4 2021, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Merus: 4,135,071 shares worth $131M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was argenx, an estimated $45.6M trimmed.

  • BVF Inc's largest Q4 2021 buy was Merus: 4,135,071 shares worth $131M.
  • BVF Inc added most to Cullinan Oncology in Q4 2021, an estimated $92.4M increase.
  • BVF Inc's biggest Q4 2021 reduction was argenx, cutting an estimated $45.6M.
  • BVF Inc fully exited Gritstone bio, Inc. Common Stock in Q4 2021, selling an estimated $16.5M.
  • BVF Inc's ten largest holdings make up 47% of its $2.76B portfolio in Q4 2021.
  • BVF Inc opened 11 new positions and closed 3 in Q4 2021.
  • BVF Inc's portfolio value rose 7.5% quarter-over-quarter to $2.76B.

Based on BVF Inc's 13F filing for Q4 2021, filed 14 Feb 2022.